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Abstract. Advanced non-small cell lung cancer (NSCLC)
remains a difficult cancer to treat, and evolution of platinum-
free regimens in a first-line setting is ongoing. This was a
dose-finding study on the docetaxel and vinorelbine com-
bination. Docetaxel was given at 60 mg/m2 on day 1 only, and
vinorelbine was given on days 1 and 15 starting at 20 mg/m2,
then escalated to 30 and 40 mg/m2 in two dose cohorts. Each
cycle lasted 28 days. The maximum tolerated dose was
60 mg/m2 docetaxel and 30 mg/m2vinorelbine. Twenty-one
patients were enrolled and showed an overall response rate of
9.5%, with stable disease documented in 33% of patients.
The dosage schedule of this combination resulted in acceptable
toxicities. The median time to progression was 5.86 months
(95% CI 2.50-9.22), and median survival was 10.96 months
(95% CI 1.42-20.51) with a 1-year survival rate of 50%. This
combination may be important for patients with NSCLC.
Introduction
There is a palliative benefit of chemotherapy for advanced
non-small cell lung cancer in previous studies and meta-
analyses in terms of survival and improvement of quality
of life (1-6). Docetaxel is active as a single agent and in
combination with platinum and non-platinum agents as
treatment in chemo-naïve or previously treated advanced
non-small cell lung cancer (NSCLC) patients. The dose-
limiting toxicity of docetaxel is short-lived neutropenia, which
develops in 75-85% of patients (7,8). However, only 12% of
patients developed neutropenic fever. In patients showing
good performance with NSCLC recurring after platinum-based
regimens, an objective response rate of 7-10% and a longer
time-to-progression compared to best supportive care (9),
vinorelbine or ifosfamide is reported with docetaxel (10). In
the TAX 326 trial, improved quality of life and survival with
docetaxel and cisplatin was demonstrated in comparison with
the combination of vinorelbine and cisplatin (11).
Vinorelbine is a third generation vinca alkaloid with
activity in NSCLC. The dose-limiting toxicity of vinorelbine
is neutropenia, with 54% of patients developing grade 3-4
neutropenia (12). Vinorelbine has response rates of 12-31%
in NSCLC (12,13). Based on the single agent activity of
vinorelbine in NSCLC, Le Chevalier et al undertook a phase
III multicenter trial comparing cisplatin and vindesine,
cisplatin and vinorelbine, and single-agent vinorelbine (14).
As anticipated, the response rate (30% overall) and median
survival (40 weeks) were significantly improved in the
cisplatin and vinorelbine arm. The most intriguing data to
emerge from this study were comparable response and
survival rates for cisplatin and vindesine (19% response rate
and 32-week median survival) and single-agent vinorelbine
(14% response rate, 31 week median survival). The results
suggest that single-agent vinorelbine is a reasonable option
for patients who might be intolerant of the nephrotoxicity,
neurotoxicity, and ototoxicity associated with cisplatin use.
Testing of docetaxel demonstrates additive to synergistic
activity with a wide variety of drugs including vinorelbine
(15,16). There is minimal overlapping toxicity except
neutropenia. With vinca alkaloids, docetaxel could be
delivered at 80-100% of the MTD without severe toxicity in
murine models and xenograft studies (16). There is schedule
dependence in cell lines treated with taxanes and vinorelbine
in vitro, with better efficacy when vinorelbine was given
before taxanes (17,18). This has not been shown specifically
for docetaxel. In a non-randomized phase II study, Sanchez
et al showed that scheduling docetaxel prior to vinorelbine
resulted in a marginally better response rate (19). 
In order to avoid excessive hematologic toxicity and
derive an effective and safe combination regimen using these
two drugs, a schedule with a long cycling interval and
docetaxel given prior to vinorelbine was chosen. A phase I
trial in patients with recurrent or newly diagnosed stage IIIB
or IV NSCLC was conducted to determine the maximum
tolerated dose and dose-limiting toxicities.
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Patients and methods
Patients were eligible for the trial if they had histologically or
cytologically confirmed stage IIIB or IV or recurrent non-
small cell lung cancer and no more than one previous
chemotherapeutic regimen. Other eligibility criteria included
an ECOG performance status of 0-2, age ≥18, and measurable
disease. Patients with previously irradiated lesions needed
documented progression to be eligible, and patients with
pleural effusions, ascites, and bone metastases were not
eligible. Adequate hematological marrow function (ANC
≥1500 cells/mm3; hematocrit ≥30%; platelets ≥100 000/mm3;
hepatic function total bilirubin ≤34 μmol/l; AST/ALT less
than twice the upper limit of normal levels); and renal
function (creatinine ≤177 μmol/l) were required.
Exclusion criteria included prior therapy with docetaxel
or vinorelbine, uncontrolled infection, pregnancy, active
CNS metastases, chemotherapy within 4 weeks prior to study
entry; nitrosourea or mitomycin C treatment within 6 weeks
prior to study entry, radiotherapy to the chest, pelvic or spine
within 4 weeks prior to study entry, known history of HIV
infection or life expectancy <3 months. Written informed
consent was obtained from all patients, and the trial was
approved by the Human Studies Committee of the Washington
University Medical Center.
Treatment schedule. This was a phase I study of once
monthly docetaxel with twice monthly vinorelbine. Vinorelbine
was administered on days 1 and 15, starting with 20 mg/m2
then dose escalated to 30 and 40 mg/m2 (Table I). Docetaxel
was administered at 60 mg/m2 on day 1 after vinorelbine
infusion in all cohorts. Both agents were given in a 28-day
cycle. Premedication with dexamethasone 8 mg po was given
twice daily for 5 days starting one day prior to docetaxel.
Six patients were accrued at each dose level. Dose escalation
occurred when the sixth patient in a cohort completed the
first cycle and only if no more than 1 of 6 patients in that
cohort experienced a DLT. If, in any cohort, 2 of 6 patients
developed DLT, dose escalation ceased and the previous
dose level was considered the maximum tolerated dose
(MTD). If no more than 1 of 6 patients at dose level 40 mg/m2
experienced DLT, this dose was considered the MTD. If any
of the six patients in any cohort did not complete the first
cycle of treatment, for reasons other than DLT, another
patient was added to replace the patient in that cohort. There
was no intra-patient dose escalation.
Dose-limiting toxicity was defined as any of the following
events: grade 4 neutropenia for >7 days or grade 4 neutropenia
associated with fever ≥38.5˚C of any duration; grade 4
thrombocytopenia; or grade >3 non-hematologic toxicity
(excluding nausea and vomiting, alopecia, anorexia,
stomatitis, and esophagitis/dysphagia) occurring during the
first cycle (28 day period) of therapy. Administration of 6
cycles of therapy was planned unless a patient developed
clear-cut disease progression or dose-limiting toxicity, or
requested withdrawal from study.
Toxicity monitoring and dose modifications. Patients underwent
a complete history and physical examination every 2 weeks
by either the principal investigator or co-investigators. Safety
assessments were based on physical examination findings, vital
signs, laboratory tests, performance status, symptoms/toxicity,
and clinical adverse events. Adverse events observed before,
during and after drug treatment administered by the study
were recorded and graded according to standard NCI
Common Toxicity Criteria version 2.
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Table I. Dose escalation schema.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Docetaxel Vinorelbine No. of No. of cycles
Cohort (mg/m2)a (mg/m2)a patients administered
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1 60 20 10 17.5
2 60 30 6 25.5
3 60 40 5 14.5
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aDocetaxel was administered on day 1 and vinorelbine was administered on days 1 and 15 of a 28-day cycle.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table II. Patient characteristics.
–––––––––––––––––––––––––––––––––––––––––––––––––
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Complete blood counts were obtained weekly, and a
comprehensive metabolic panel was obtained prior to the start
of each cycle. Therapy was delayed by one week for ANC
≤1500 cells/mm3 or platelets ≤25,000/mm3. The vinorelbine
dose was reduced by 25% for the remaining treatments if
either of these events resulted in a delay lasting >7 days or a
fever ≥38.5˚C associated with an ANC ≤500 cells/mm3 of any
duration. A second reduction of 25% was made if a patient
had a subsequent episode that met these criteria.
Response criteria. Patient response was evaluated after every 2
cycles of treatment. Response data were collected and defined
according to World Health Organisation (WHO) criteria (20).
Results
Patient characteristics. There were 21 patients enrolled in
the trial between February 1998 and May 2000. The baseline
patient characteristics are described in Table II. Five patients
had stage IIIB and 16 patients had stage IV disease. Most of
the patients were male. A majority had a performance status
of 1. Two patients received previous chemotherapy, and 9
patients had prior radiotherapy.
Dose escalation was done in the manner described (Table I).
In cohort 1, patient 4 had an episode of febrile neutropenia,
and it was decided to add six more patients to this cohort. Of
these six additional patients, two did not complete cycle 1
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Cohort Docetaxel Vinorelbine ANC x103/μld Hb g/dld Plts x103/μld
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1 60 20 3.70 (0.00-13.72) 10.8 (7.3-13.6) 223 (166-302)
2 60 30 1.80 (0.03-9.25) 10.2 (8.0-11.4) 208 (106-304)





Cohort Docetaxel Vinorelbine ANC x103/μld Hb g/dld Plts x103/μld
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1 60 20a 3.47 (0.16-8.66) 11.6 (9.5-12.9) 278 (165-587)
2 60 30b 0.56 (0.01-2.20) 9.3 (7.3-10.7) 292 (69-760)
3 60 40c - - -
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aIncludes 2 cycles administered to one patient enrolled in cohort 2, but dose-reduced to the doses in this cohort because of grade 4
neutropenia. bExcludes 2 cycles administered to one patient whose vinorelbine was dose-reduced twice to 15 mg/m2 and not included in this
analyses, includes 8 cycles from three patients enrolled in cohort 3 and subsequently dose reduced, and excludes 2 cycles from one patient
whose dose of docetaxel and vinorelbine were reduced due to grade 4 neutropenia. cAll five patients enrolled at this level received only 1
cycle and were dose reduced due to myelosuppression. dData expressed as mean nadir count (range).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table IV. Non-hematologic cycle 1.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Cohort 1 Cohort 2 Cohort 3
–––––––––––––––––––––– –––––––––––––––––––––– ––––––––––––––––––––––
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
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due to a gunshot wound and severe depression, respectively.
As there was no other DLT in these patients attributed to the
study agents, patients were entered in cohort 2. Four patients
in cohort 2 had greater than grade 4 neutropenia, and one
required dose reduction. One patient had a seizure-like
reaction within minutes of infusion of docetaxel. The infusion
was stopped and given the next day without incident. The
etiology of this grade 3 non-hematologic event was unclear,
and five other patients were treated without incident. Patients
were then enrolled in cohort 3. Five patients in this cohort
received only 1 cycle of chemotherapy as two of them had
DLTs defined as neutropenic fever, and dose reductions were
subsequently required. The MTD was therefore determined
to be 60 mg/m2 docetaxel on day 1 and 30 mg/m2 vinorelbine
on days 1 and 15.
Toxicities. Encountered toxicities are shown in Tables III and
IV. The main hematologic toxicity encountered was grade
3/4 neutropenia in eleven (52%) patients (Table III). Three
(14%) patients had neutropenic fever. A reduction in the dose
of vinorelbine was required for two patients in cohort 2 and
all five patients in cohort 3. Per investigator discretion, 1
of the five patients in cohort 3 was administered a dose
reduction of vinorelbine and docetaxel. None of the patients
required growth factor support or prophylaxis. The frequency
of grades 3 and 4 non-hematologic toxicities was <5% at
each dose level. There was no treatment-related mortality. 
Response and survival. All analyses were on an intent-to-
treat basis. Only four patients completed the planned 6 cycles
of therapy. Most patients completed between 2 to 4 cycles of
treatment (median =2). There were 16 patients who were
evaluable for response (Table V). Partial response was achieved
in two patients (9.5%) in cohort 2. There were no complete
responses. Stable disease was achieved in 4 (19.0%) patients. 
Discussion
Several chemotherapeutic agents such as taxanes, topoiso-
merase I inhibitors, gemcitabine and vinorelbine have
documented single agent activity in NSCLC. Platinum-based
combination therapy with these newer agents is the current
standard of care in advanced NSCLC. A comparison of these
different platinum-based regimens in treatment of naïve
patients does not show clear benefit of one over the other in
terms of survival, and the overall impact of these regimens
on survival remains modest (21). 
Non-platinum combinations may be associated with
decreased toxicity and improved efficacy. Several investi-
gations in a first-line setting have studied the administration
of docetaxel and vinorelbine at 3 weekly intervals (22,23).
This resulted in high rates of grade 3/4 neutropenia and some
treatment-related mortality as a result of neutropenic sepsis.
Response rates were 27.0% and 36.6% in the two above-
mentioned studies. The concomitant use of prophylactic
filgastrim support allowed the use of 60 mg/m2 docetaxel and
45 mg/m2 vinorelbine given every 2 weeks in a chemo-naïve
population (24,25). Overall response rates of 51% were
achieved with acceptable rates of febrile neutropenia. In the
salvage setting, weekly doses of docetaxel and vinorelbine
also had significant hematological toxicity. In one study
dose modifications were required in 91% of patients (26); in
another trial, toxicity was unacceptable and the trial was
stopped without producing any meaningful response (27). 
In this dose-finding study, the MTD was determined to be
60 mg/m2 docetaxel on day 1, and 30 mg/m2 vinorelbine on
days 1 and 15. Hematologic toxicities in the absence of
prophylactic growth factor support are among the lowest in
all phase I/II studies described so far.
The overall response rate was only 9.5%. Though the
response rate is low, stable disease was achieved in 33% of
patients. In patients with recurrent and advanced disease,
achieving stable disease with low toxicity constitutes an
important palliative endpoint (28). This is more significant in
light of current data that support limiting the administration
of chemotherapy to 3-4 cycles in patients with newly
diagnosed advanced NSCLC (29,30). Although an endpoint
was not specified in this trial, the median time to progression
and median survival achieved are comparable to historical
data of current first-line platinum-based regimens. This is
encouraging and supports further investigation of non-
platinum-containing regimens. Nevertheless, interpretation
across studies and the small number of patients in this study
limit further conclusions. 
Docetaxel and vinorelbine dosed according to the schedule
in this study have a tolerable toxicity profile and achieve
responses and rates of stable disease that translate into a
meaningful duration of response and survival. Dose-limiting
toxicity was neutropenia. This remains an important
combination for patients with advanced NSCLC. Future
studies of docetaxel will need to exploit synergism with other
drugs that can improve efficacy without concomitant dose-
limiting toxicity.
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